These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 22236867

  • 1. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
    Li Y, Fan S, Koo J, Yue P, Chen ZG, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY.
    Cancer Biol Ther; 2012 Mar; 13(5):272-80. PubMed ID: 22236867
    [Abstract] [Full Text] [Related]

  • 2. Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
    Patel MR, Jay-Dixon J, Sadiq AA, Jacobson BA, Kratzke RA.
    J Thorac Oncol; 2013 Sep; 8(9):1142-7. PubMed ID: 23883783
    [Abstract] [Full Text] [Related]

  • 3. Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer.
    Pang W, Tian X, Bai F, Han R, Wang J, Shen H, Zhang X, Liu Y, Yan X, Jiang F, Xing L.
    Mol Cancer; 2014 Oct 24; 13():240. PubMed ID: 25342548
    [Abstract] [Full Text] [Related]

  • 4. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY, Lam SK, Mak JC, Zheng CY, Ho JC.
    Lung Cancer; 2013 Sep 24; 81(3):354-361. PubMed ID: 23769318
    [Abstract] [Full Text] [Related]

  • 5. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.
    Zhongguo Fei Ai Za Zhi; 2012 Dec 24; 15(12):689-93. PubMed ID: 23249714
    [Abstract] [Full Text] [Related]

  • 6. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T.
    J Thorac Oncol; 2011 Jul 24; 6(7):1152-61. PubMed ID: 21597390
    [Abstract] [Full Text] [Related]

  • 7. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.
    Lung Cancer; 2014 Aug 24; 85(2):152-60. PubMed ID: 24954871
    [Abstract] [Full Text] [Related]

  • 8. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
    Milligan SA, Burke P, Coleman DT, Bigelow RL, Steffan JJ, Carroll JL, Williams BJ, Cardelli JA.
    Clin Cancer Res; 2009 Aug 01; 15(15):4885-94. PubMed ID: 19638461
    [Abstract] [Full Text] [Related]

  • 9. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
    Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, Weiss GJ, Kingsley CB, Loftus JC, Bremner R, Tran NL, Winkles JA.
    Am J Pathol; 2012 Jul 01; 181(1):111-20. PubMed ID: 22634180
    [Abstract] [Full Text] [Related]

  • 10. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1.
    Chen J, Cui JD, Guo XT, Cao X, Li Q.
    Cancer Med; 2018 Apr 01; 7(4):1394-1403. PubMed ID: 29493886
    [Abstract] [Full Text] [Related]

  • 11. Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.
    Ghosh G, Lian X, Kron SJ, Palecek SP.
    BMC Cancer; 2012 Mar 20; 12():95. PubMed ID: 22433462
    [Abstract] [Full Text] [Related]

  • 12. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
    Ling YH, Li T, Yuan Z, Haigentz M, Weber TK, Perez-Soler R.
    Mol Pharmacol; 2007 Aug 20; 72(2):248-58. PubMed ID: 17456787
    [Abstract] [Full Text] [Related]

  • 13. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 14. Oncogenic miR-9 is a target of erlotinib in NSCLCs.
    Chen X, Zhu L, Ma Z, Sun G, Luo X, Li M, Zhai S, Li P, Wang X.
    Sci Rep; 2015 Nov 23; 5():17031. PubMed ID: 26593208
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer.
    Xie C, Jin J, Bao X, Zhan WH, Han TY, Gan M, Zhang C, Wang J.
    Oncotarget; 2016 Jan 05; 7(1):610-21. PubMed ID: 26575584
    [Abstract] [Full Text] [Related]

  • 16. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z, Yuan T, Zhou X, Ni P, Sun G, Li P, Cheng Z, Wang X.
    Cancer Biol Ther; 2018 May 04; 19(5):407-415. PubMed ID: 29333921
    [Abstract] [Full Text] [Related]

  • 17. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.
    Mol Cancer Ther; 2015 Feb 04; 14(2):533-41. PubMed ID: 25522765
    [Abstract] [Full Text] [Related]

  • 18. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
    Serizawa M, Takahashi T, Yamamoto N, Koh Y.
    J Thorac Oncol; 2013 Mar 04; 8(3):259-69. PubMed ID: 23334091
    [Abstract] [Full Text] [Related]

  • 19. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C.
    Mol Cancer Ther; 2009 Dec 04; 8(12):3296-306. PubMed ID: 19952121
    [Abstract] [Full Text] [Related]

  • 20. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.
    Liao J, Lin J, Lin D, Zou C, Kurata J, Lin R, He Z, Su Y.
    Sci Rep; 2017 Apr 10; 7(1):781. PubMed ID: 28396596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.